ArticleImmunity, inflammation and disease2026
Microbiome Landscapes in Squamous Cell Carcinoma Tissue Microenvironments: A Comparative Analysis.
Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Microbiome Landscapes in Squamous Cell Carcinoma Tissue Microenvironments: A Comparative Analysis.Immunity, inflammation and disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionSquamous cell carcinoma (SCC) is one of the most prevalent human cancers. While anatomically distinct, SCCs exhibit diverse similarities in etiology and molecular. The extent to which different SCCs share microbial landscapes within the tumor tissue microenvironment remains unclear.
methodsWe analyzed RNA sequencing data from 419 SCC samples across five anatomical sites: cutaneous (CuSCC), esophageal (ESCC), lung (LSCC), head and neck (HNSCC), and cervical (CeSCC). Differential microbial abundance between tumor and adjacent normal tissue was assessed using multivariable linear models implemented in MaAsLin2. For each anatomical site, an independent external validation cohort was included (totaling 156 samples) to validate key microbial findings using the area under the receiver operating characteristic curve (AUROC).
resultsThe five SCC cohorts shared 28 shared core bacterial genera, with Staphylococcus was widespread and had the highest relative abundance (mean 13.74%) in all cohorts. ESCC, HNSCC, and LSCC exhibited more similar dysregulated microbiota, with Clostridioides showing the most significant up-regulation in tumor relative to adjacent tissue (the mean model coefficient value, coef = 3.26). Notably, Bradyrhizobium (CeSCC, CuSCC, LSCC, mean coef = -2.58), Massilia (in CeSCC, ESCC, HNSCC, mean coef = -1.99), Providencia (in CeSCC, HNSCC, LSCC, mean coef = 0.93), and Ralstonia (in CuSCC, ESCC, HNSCC, mean coef = -0.52) displayed significant differential expression across multiple cohorts, as confirmed in the validation cohorts (AUROC > 0.6).
conclusionsDespite the absence of a common dysbiotic microbiota among SCCs due to anatomical differences, potential similarities in adjacent sites suggest a unified disease perspective and may pave the way for novel preventive and therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.